The significance of immunohistochemistry positivity in sentinel nodes which are negative on haematoxylin and eosin in breast cancer

Giobuin, S Mac; Kavanagh, Dara; Myers, E.; Doherty, Ann O'; Quinn, Cecily; Crotty, T. P.; Evoy, Denis; McDermott, Enda

doi:10.1016/j.ejso.2009.04.004

Cited by 13 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, identification of a significant number of metastases larger than 2 mm (9.9%) is worth noting. Giobuin et al [13] and Choi et al [15] presented different results. In their studies, all diagnosed macrometastases were detected using routine staining methods (HE).…”

Section: Discussionmentioning

confidence: 90%

Application of immunohistochemistry for detection of metastases in sentinel lymph nodes of non-advanced breast cancer patients

Nowikiewicz¹,

Śrutek²,

Zegarski³

2015

pjp

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

Application of immunohistochemistry for detection of metastases in sentinel lymph nodes of non-advanced breast cancer patients

Nowikiewicz¹,

Śrutek²,

Zegarski³

2015

pjp

View full text Add to dashboard Cite

“…The percentage of axillary lymph node recurrences in patients after ALND performed after SLNB with positive SLN histopathology amounted to 1.2%. Giobuin et al [16] point to the occurrence of non-sentinel lymph node metastatic lesions in patients with SLN micrometastases or ITC. Among 1076 patients undergoing SLNB, lymph node changes identified only with IHC were diagnosed in 49 subjects.…”

Section: Discussionmentioning

confidence: 99%

Management and results of treatment of breast cancer patients having sentinel lymph node micrometastases

Nowikiewicz¹,

Śrutek²,

Jankowski³

et al. 2014

neo

View full text Add to dashboard Cite

According to current therapeutic guidelines, finding micrometastases in the sentinel node (SLN) of a patient with non-advanced breast cancer is not an absolute indication for adjuvant axillary lymph node dissection (ALND). This work presents our experiences regarding this clinical problem. 1071 breast cancer patients were referred for sentinel node biopsy between January 2004 and December 2011. Metastases were found in 245 of the removed lymph nodes. In 49 patients lymph node changes turned out to be micrometastases or isolated tumor cells (ITC). ALND was performed in 38 cases of sentinel node micrometastases or ICTs. In three patients involvement of other axillary lymph nodes was found in the studied tissue material (7.9% vs. 37.9% for metastases >2mm). The remaining patients with micrometastases in the SLN (11/49) were treated conservatively. No local axillary recurrences or neoplastic metastases were found in this group of patients with SLN micrometastases. Mean follow-up period in patients who had undergone ALND was 18.0 months (4 to 60 months) and 21.4 months (9-40 months) in patients without ALND. Non-radical surgical treatment in the presence of SLN micrometastases in patients with non-advanced breast cancer does not lead to therapeutic failure (local axillary recurrences, distant metastases). Obtaining favorable outcomes of conservative treatment in the analyzed group of patients does not require additional modification of the adjuvant therapy.

show abstract

“…The surgeons at the St Vincent's University Hospital in Dublin, Ireland performed SN mapping for breast cancer from January 1st, 2000 to December 31st, 2006 [40]. All SNs were assessed by serial H&E and IHC sections.…”

Section: Resultsmentioning

confidence: 99%

Issues Related to Sentinel Lymph Node Assessment in the Management of Breast Cancer—What Are Relevant in Pathology Reports?

Tai¹,

Joseph

2011

Pathology Research International

View full text Add to dashboard Cite

Most cancer centers now perform sentinel node (SN) biopsies. The limited number of SNs sampled compared with an axillary dissection has allowed more comprehensive lymph node analysis resulting in increased detection of micrometastases. Many node-negative cases are now reclassified as micrometastatic. Recent research on SN biopsy focuses on whether axillary dissection is always necessary when the SN is positive. Some subgroups of patients have a higher risk of more nodal metastases when completion axillary dissections were performed. This paper summarizes the different studies and examines what are the clinically relevant items to report on SN node pathology: volume or size of nodal metastasis, location within the node, extranodal extension, number of involved SN(s) and non-SN(s), total number of SN, and total number of nodes on axillary dissection, if performed.

show abstract

The significance of immunohistochemistry positivity in sentinel nodes which are negative on haematoxylin and eosin in breast cancer

Cited by 13 publications

References 11 publications

Application of immunohistochemistry for detection of metastases in sentinel lymph nodes of non-advanced breast cancer patients

Application of immunohistochemistry for detection of metastases in sentinel lymph nodes of non-advanced breast cancer patients

Management and results of treatment of breast cancer patients having sentinel lymph node micrometastases

Issues Related to Sentinel Lymph Node Assessment in the Management of Breast Cancer—What Are Relevant in Pathology Reports?

Contact Info

Product

Resources

About